Back to top
more

West Pharmaceutical Services (WST)

(Delayed Data from NYSE)

$349.92 USD

349.92
440,220

+1.44 (0.41%)

Updated Aug 26, 2026 04:02 PM ET

After-Market: $349.92 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (71 out of 247)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Reasons to Retain West Pharmaceutical Stock in Your Portfolio for Now

by Zacks Equity Research

WST leans on strong HVP demand, rising GLP-1 exposure and Annex 1 tailwinds, even as pricing and device margins weigh on near-term performance.

Zacks Equity Research

Why Is McKesson (MCK) Down 5.2% Since Last Earnings Report?

by Zacks Equity Research

McKesson (MCK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Why Is Henry Schein (HSIC) Up 1.2% Since Last Earnings Report?

by Zacks Equity Research

Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

RGTI Stock Down Despite Q3 Earnings Top Estimates, Revenues Decline Y/Y

by Zacks Equity Research

Rigetti's Q3 loss is narrower than estimates, but revenues decline as government contract delays hit sales and lower the gross margin.

Zacks Equity Research

AMN Stock Gains Following Q3 Earnings & Revenue Beat, Margins Down

by Zacks Equity Research

AMN Healthcare beats third-quarter 2025 earnings and revenue estimates despite lower margins and year-over-year declines across key segments.

Zacks Equity Research

Doximity Stock Down Despite Q2 Earnings Beat, Revenues Up Y/Y

by Zacks Equity Research

DOCS Q2 results benefit from the rise in AI-driven engagement. However, the stock plunges nearly 9% in pre-market trading.

Zacks Equity Research

QuidelOrtho Q3 Earnings and Revenues Beat Estimates, Margins Expand

by Zacks Equity Research

QDEL tops Q3 estimates as Labs and Immunohematology units drive growth, while margins strengthen despite respiratory revenue declines.

Zacks Equity Research

Inogen Stock Dips Despite Q3 Earnings Beat, Revenues Up Y/Y

by Zacks Equity Research

INGN stock slid despite a narrower Q3 loss and rising B2B demand, as weaker consumer and rental sales weighed on results.

Zacks Equity Research

PACB Stock Down Despite Q3 Earnings Beat Estimates, Revenues Down Y/Y

by Zacks Equity Research

PacBio posts a narrower Q3 loss and margin gains, but shares fall as revenues dip amid softer instrument demand.

Zacks Equity Research

CONMED Q3 Earnings and Revenues Beat Estimates, Margins Contract

by Zacks Equity Research

CNMD beats third-quarter 2025 estimates on strength in surgery segments, but gross and operating margins see sharp contraction.